97
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Multiple Congenital Melanocytic Nevi and Neurocutaneous Melanosis Are Caused by Postzygotic Mutations in Codon 61 of NRAS

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Congenital melanocytic nevi (CMN) can be associated with neurological abnormalities and an increased risk of melanoma. Mutations in NRAS, BRAF, and Tp53 have been described in individual CMN samples; however, their role in the pathogenesis of multiple CMN within the same subject and development of associated features has not been clear. We hypothesized that a single postzygotic mutation in NRAS could be responsible for multiple CMN in the same individual, as well as for melanocytic and nonmelanocytic central nervous system (CNS) lesions. From 15 patients, 55 samples with multiple CMN were sequenced after site-directed mutagenesis and enzymatic digestion of the wild-type allele. Oncogenic missense mutations in codon 61 of NRAS were found in affected neurological and cutaneous tissues of 12 out of 15 patients, but were absent from unaffected tissues and blood, consistent with NRAS mutation mosaicism. In 10 patients, the mutation was consistently c.181C>A, p.Q61K, and in 2 patients c.182A>G, p.Q61R. All 11 non-melanocytic and melanocytic CNS samples from 5 patients were mutation positive, despite NRAS rarely being reported as mutated in CNS tumors. Loss of heterozygosity was associated with the onset of melanoma in two cases, implying a multistep progression to malignancy. These results suggest that single postzygotic NRAS mutations are responsible for multiple CMN and associated neurological lesions in the majority of cases.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

          To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer. In part A, patients received escalating doses to determine the maximum-tolerated dose (MTD). In both parts, blood samples were collected to assess PK and PD parameters. In part B, patients were stratified by cancer type (melanoma v other) and randomly assigned to receive the MTD or 50% MTD. Biopsies were collected to determine inhibition of ERK phosphorylation, Ki-67 expression, and BRAF, KRAS, and NRAS mutations. Fifty-seven patients were enrolled. MTD in part A was 200 mg bid, but this dose was discontinued in part B because of toxicity. The 50% MTD (100 mg bid) was well tolerated. Rash was the most frequent and dose-limiting toxicity. Most other adverse events were grade 1 or 2. The PKs were less than dose proportional, with a median half-life of approximately 8 hours and inhibition of ERK phosphorylation in peripheral-blood mononuclear cells at all dose levels. Paired tumor biopsies demonstrated reduced ERK phosphorylation (geometric mean, 79%). Five of 20 patients demonstrated >or= 50% inhibition of Ki-67 expression, and RAF or RAS mutations were detected in 10 of 26 assessable tumor samples. Nine patients had stable disease (SD) for >or= 5 months, including two patients with SD for 19 (thyroid cancer) and 22 (uveal melanoma plus renal cancer) 28-day cycles. AZD6244 was well tolerated with target inhibition demonstrated at the recommended phase II dose. PK analyses supported twice-daily dosing. Prolonged SD was seen in a variety of advanced cancers. Phase II studies are ongoing.
            • Record: found
            • Abstract: found
            • Article: not found

            Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.

            Nevus sebaceous is a common congenital cutaneous malformation. Affected individuals may develop benign and malignant secondary tumors in the nevi during life. Schimmelpenning syndrome is characterized by the association of nevus sebaceous with extracutaneous abnormalities. We report that of 65 sebaceous nevi studied, 62 (95%) had mutations in the HRAS gene and 3 (5%) had mutations in the KRAS gene. The HRAS c.37G>C mutation, which results in a p.Gly13Arg substitution, was present in 91% of lesions. Nonlesional tissues from 18 individuals had a wild-type sequence, confirming genetic mosaicism. The HRAS c.37G>C mutation was also found in 8 of 8 associated secondary tumors. Mosaicism for HRAS c.37G>C and KRAS c.35G>A mutations was found in two individuals with Schimmelpenning syndrome. Functional analysis of HRAS c.37G>C mutant cells showed constitutive activation of the MAPK and PI3K-Akt signaling pathways. Our results indicate that nevus sebaceous and Schimmelpenning syndrome are caused by postzygotic HRAS and KRAS mutations. These mutations may predispose individuals to the development of secondary tumors in nevus sebaceous.
              • Record: found
              • Abstract: found
              • Article: not found

              A restricted spectrum of NRAS mutations causes Noonan syndrome.

              Noonan syndrome, a developmental disorder characterized by congenital heart defects, reduced growth, facial dysmorphism and variable cognitive deficits, is caused by constitutional dysregulation of the RAS-MAPK signaling pathway. Here we report that germline NRAS mutations conferring enhanced stimulus-dependent MAPK activation account for some cases of this disorder. These findings provide evidence for an obligate dependency on proper NRAS function in human development and growth.

                Author and article information

                Journal
                J Invest Dermatol
                J. Invest. Dermatol
                The Journal of Investigative Dermatology
                Nature Publishing Group
                0022-202X
                1523-1747
                September 2013
                07 February 2013
                21 March 2013
                : 133
                : 9
                : 2229-2236
                Affiliations
                [1 ]Paediatric Dermatology Department, Great Ormond Street Hospital for Children , London, UK
                [2 ]Clinical and Molecular Genetics Unit, UCL Institute of Child Health , London, UK
                [3 ]Paediatric Plastic Surgery Department, Great Ormond Street Hospital for Children , London, UK
                [4 ]Regional Genetics Laboratory, Great Ormond Street Hospital for Children , London, UK
                [5 ]Paediatric Malignancy Unit, Great Ormond Street Hospital for Children , London, UK
                [6 ]Paediatric Pathology Department, Royal Hospital for Sick Children , Edinburgh, UK
                [7 ]Paediatric Oncology Department, Great Ormond Street Hospital for Children , London, UK
                [8 ]GOSgene, UCL Institute of Child Health , London, UK
                [9 ]Neural Development Unit, UCL Institute of Child Health , London, UK
                [10 ]Dermatopharmacology Unit, Sir Henry Wellcome Laboratories, University of Southampton , Southampton, UK
                [11 ]Paediatric Pathology Department, Great Ormond Street Hospital for Children , London, UK
                [12 ]Cancer Biology Unit, UCL Institute of Child Health , London, UK
                Author notes
                [* ]Paediatric Dermatology Department, Great Ormond Street Hospital for Children , London WC1N 3JH, UK. E-mail: v.kinsler@ 123456ucl.ac.uk
                Article
                jid201370
                10.1038/jid.2013.70
                3678977
                23392294
                0f289f2e-c32f-4464-8829-8df5d299ac7c
                Copyright © 2013 The Society for Investigative Dermatology, Inc

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

                History
                : 15 October 2012
                : 06 December 2012
                : 02 January 2013
                Categories
                Original Article

                Dermatology
                Dermatology

                Comments

                Comment on this article

                Related Documents Log